Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050306 | 1.00 | MAPT (0.69) | MAPTHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL9425659 | 0.86 | MAPT (0.67) | MAPTHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL1710516 | 0.84 | MAPT (0.65) | MAPTHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL20189964 | 0.84 | MAPT (0.50) | MAPTHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL4555801 | 0.82 | SMN1; SMN2 (0.53) | MAPTHTTPOLBLMNAMAPK1 | |
| SCHEMBL20189765 | 0.82 | MAPT (0.49) | MAPTHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL15771279 | 0.82 | CYP3A4 (0.52) | MAPTHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL4437996 | 0.82 | MAPT (0.53) | MAPTHTTPOLBLMNAMAPK1 | |
| SCHEMBL15771015 | 0.81 | MAPT (0.48) | MAPTHTTPOLBCYP1A2CYP2C9 | |
| SCHEMBL20189504 | 0.80 | MAPT (0.47) | MAPTHTTPOLBCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-108373476-B | Kinase inhibitor and preparation and application thereof | 成都地奥制药集团有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3544980-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-3066093-B9 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3066093-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276463-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | MAPT 81/4885HTT 2452/4885POLB 1008/4885 |
| US-10774086-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | MAPT 81/4885HTT 2452/4885POLB 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.